FGFR2 and intrahepatic cholangiocarcinoma: By contrast, FGFR2 SVs/REs most commonly occurred in cholangiocarcinoma (SVs: 162/7729, 2.1%; REs: 647/7729, 8.4%), specifically intrahepatic cholangiocarcinoma (SVs: 159/6641, 2.4%; REs: 618/6641, 9.3%), extrahepatic cholangiocarcinoma (SVs: 16/993, 1.6%; REs: 39/993, 3.9%), and mixed hepatocellular carcinoma (SVs: 1/95, 1.1%; REs: 4/95, 4.2%; Figure 2B).